173 related articles for article (PubMed ID: 31455836)
41. Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness.
Leung TH; Tang HW; Siu MK; Chan DW; Chan KK; Cheung AN; Ngan HY
J Pathol; 2018 Feb; 244(2):151-163. PubMed ID: 28944962
[TBL] [Abstract][Full Text] [Related]
42. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells.
Rampias T; Boutati E; Pectasides E; Sasaki C; Kountourakis P; Weinberger P; Psyrri A
Mol Cancer Res; 2010 Mar; 8(3):433-43. PubMed ID: 20215420
[TBL] [Abstract][Full Text] [Related]
43. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
44. Inhibitory effect of Lonicera japonica-derived exosomal miR2911 on human papilloma virus.
Chi Y; Shi L; Lu S; Cui H; Zha W; Shan L; Shen Y
J Ethnopharmacol; 2024 Jan; 318(Pt B):116969. PubMed ID: 37516391
[TBL] [Abstract][Full Text] [Related]
45. HPV-inactive cell populations arise from HPV16-transformed human keratinocytes after p53 knockout.
Abboodi F; Buckhaults P; Altomare D; Liu C; Hosseinipour M; Banister CE; Creek KE; Pirisi L
Virology; 2021 Feb; 554():9-16. PubMed ID: 33321328
[TBL] [Abstract][Full Text] [Related]
46. Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma.
Liu WL; Green N; Seymour LW; Stevenson M
Cancer Gene Ther; 2009 Oct; 16(10):764-75. PubMed ID: 19363466
[TBL] [Abstract][Full Text] [Related]
47. Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes.
Nishida H; Matsumoto Y; Kawana K; Christie RJ; Naito M; Kim BS; Toh K; Min HS; Yi Y; Matsumoto Y; Kim HJ; Miyata K; Taguchi A; Tomio K; Yamashita A; Inoue T; Nakamura H; Fujimoto A; Sato M; Yoshida M; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Nishiyama N; Kataoka K; Osuga Y; Fujii T
J Control Release; 2016 Jun; 231():29-37. PubMed ID: 26979870
[TBL] [Abstract][Full Text] [Related]
48. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
[TBL] [Abstract][Full Text] [Related]
49. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
50. Fused toes homolog, a potential molecular regulator of human papillomavirus type 16 E6 and E7 oncoproteins in cervical cancer.
D S P; Chaturvedi PK; Krishnamoorthy D; Seo YS; Thippana M; Park WY
PLoS One; 2022; 17(4):e0266532. PubMed ID: 35421154
[TBL] [Abstract][Full Text] [Related]
51. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of TRAIL treatment against HPV16 infected cervical cancer cells undergoing senescence following siRNA knockdown of E6/E7 genes.
Eaton S; Wiktor P; Thirstrup D; Lake D; Nagaraj VJ
Biochem Biophys Res Commun; 2011 Feb; 405(1):1-6. PubMed ID: 21167816
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic Utility of HPV16 E6 mRNA or E7 mRNA Quantitative Expression for Cervical Cells of Patients with Dysplasia and Carcinoma.
Wu MZ; Li WN; Cha N; Tian LX; Zhang YI; Wu X; Guo KJ; Wu GP
Cell Transplant; 2018 Sep; 27(9):1401-1406. PubMed ID: 30056761
[TBL] [Abstract][Full Text] [Related]
54. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
55. [Reversal effect of antisense RNA targeting human papillomavirus 16 (HPV16) E6E7 on malignancy of human cervical cancer cell line SiHa].
Sima N; Wang W; Xu Q; Tian X; Luo AY; Lu YP; Wang SX; Ma D
Ai Zheng; 2007 Jan; 26(1):26-31. PubMed ID: 17222363
[TBL] [Abstract][Full Text] [Related]
56. CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice.
Jubair L; Lam AK; Fallaha S; McMillan NAJ
PLoS One; 2021; 16(1):e0223288. PubMed ID: 33411765
[TBL] [Abstract][Full Text] [Related]
57. Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo.
Wang W; Sima N; Kong D; Luo A; Gao Q; Liao S; Li W; Han L; Wang J; Wang S; Lu Y; Wang D; Xu G; Zhou J; Meng L; Ma D
Cancer Lett; 2010 May; 291(1):67-75. PubMed ID: 19903581
[TBL] [Abstract][Full Text] [Related]
58. HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study.
Economopoulou P; Koutsodontis G; Avgeris M; Strati A; Kroupis C; Pateras I; Kirodimos E; Giotakis E; Kotsantis I; Maragoudakis P; Gorgoulis V; Scorilas A; Lianidou E; Psyrri A
PLoS One; 2019; 14(5):e0215984. PubMed ID: 31071126
[TBL] [Abstract][Full Text] [Related]
59. Genome editing mRNA nanotherapies inhibit cervical cancer progression and regulate the immunosuppressive microenvironment for adoptive T-cell therapy.
Ling K; Dou Y; Yang N; Deng L; Wang Y; Li Y; Yang L; Chen C; Jiang L; Deng Q; Li C; Liang Z; Zhang J
J Control Release; 2023 Aug; 360():496-513. PubMed ID: 37423524
[TBL] [Abstract][Full Text] [Related]
60. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer.
Yamato K; Yamada T; Kizaki M; Ui-Tei K; Natori Y; Fujino M; Nishihara T; Ikeda Y; Nasu Y; Saigo K; Yoshinouchi M
Cancer Gene Ther; 2008 Mar; 15(3):140-53. PubMed ID: 18157144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
